▎WuXi AppTec Content Team Report

According to the press release, the proceeds from this round of financing will be used to advanceiView TherapeuticsClinical trials and registration of R&D pipeline projects, mainly supporting the R&D of iView Therapeutics, Inc.Innovative Target Treatment for Dry Eye Disease: IVW-1001, a Class 1 Novel Chemical DrugThe clinical research has been completed at 10 clinical centers in the United States, where all patients in the Phase 1/2 clinical study for the treatment of dry eye disease have been treated. Topline data is expected to be released in Q1 2025. After evaluating the clinical data, a meeting will be held with the FDA to determine the next pivotal clinical study.

In addition, iView TherapeuticsDeveloped byBroad-Spectrum Acute Treatment for ConjunctivitisThe IVIEW-1201 ProjectHave completed Phase 2 clinical studies,Submit Phase 3 Clinical Trial Application for Bacterial Conjunctivitis to U.S. FDA by End of 2024，Expected to submit Phase 3 clinical trial application for the treatment of adenoviral conjunctivitis to the FDA in 2025.iView TherapeuticsSelf-developedInnovative Ophthalmic Gene Therapy for Glaucoma ProjectBased on favorable preclinical safety and efficacy data, the First In Human clinical trial will be initiated in Q1 2025.

Dr. Liang Bo of iView Therapeutics stated: "The year 2024 is a significant milestone for iView Therapeutics in its development. The pipeline projects have successfully completed their phased research ahead of schedule, which has given us great confidence to smoothly advance to the next stage. Currently, the company's R&D pipeline covers...Dry Eye Syndrome, Infectious Conjunctivitis, Myopia, GlaucomaIn ophthalmic treatment areas where the market urgently needs solutions. We are very grateful for the recognition and support from both new and existing investors, which further strengthens our commitment to continuously develop innovative drugs and therapies in the ophthalmology field, overcome current treatment bottlenecks, and provide better solutions for patients."

Ms. Li Jingjie, General Manager of Chongqing Changsheng Shenghe, stated: "Although innovative ophthalmic drugs do not receive as much market attention as novel oncology drugs, the market opportunities in the ophthalmology field are gradually being explored and valued. iView Therapeutics focuses on innovative R&D in ophthalmology, with a pipeline covering major diseases in clinical ophthalmic treatment, and its products have promising commercialization prospects. Dr. Liang Bo, the founder of the company, is not only a professional research scientist but also an entrepreneur with successful founding experience, which is one of the reasons that attracted our investment."

Proxima Ventures, which continues to invest in iView Therapeutics, stated that the ophthalmic pharmaceuticals market holds tremendous opportunities. With its forward-looking strategy and strong R&D capabilities, iView Therapeutics is poised to offer global patients higher quality and more efficient treatment options. Proxima Ventures will continue to adhere to its long-term investment philosophy, fully supporting iView Therapeutics' future development, aiding its steady progress in the field of innovative ophthalmic treatments, and contributing greater efforts to innovation and advancement in the ophthalmic drug sector.

References:

[1] iView Therapeutics Completes New Round of Financing, Continues to Focus on Innovative Ophthalmic Treatments. Retrieved Jan 17，2025, from https://mp.weixin.qq.com/s/LbkrEm42jk4HWrcDonOU8g